Arrowstreet Capital Limited Partnership Reduces Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Arrowstreet Capital Limited Partnership lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 26.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 634,369 shares of the medical research company’s stock after selling 233,143 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Thermo Fisher Scientific were worth $311,811,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Assetmark Inc. grew its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares during the period. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $7,505,000. Northstar Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $3,250,000. Eagle Rock Investment Company LLC increased its position in Thermo Fisher Scientific by 15.9% during the 4th quarter. Eagle Rock Investment Company LLC now owns 21,969 shares of the medical research company’s stock valued at $12,730,000 after buying an additional 3,012 shares in the last quarter. Finally, Boston Trust Walden Corp raised its stake in Thermo Fisher Scientific by 9.7% during the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after buying an additional 3,873 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
• Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
• Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
• Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
• Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $567.34 on Friday. The stock has a 50-day moving average price of $494.01 and a 200 day moving average price of $513.46. The stock has a market capitalization of $210.83 billion, a P/E ratio of 30.52, a P/E/G ratio of 2.51 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.15 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the company posted $4.28 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.08 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Analysts Set New Price Targets

A number of research firms have recently commented on TMO. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Morgan Stanley restated an “overweight” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $613.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.